- Home
- RCUS vs BCSF Comparison
RCUS vs BCSF Comparison
Compare RCUS & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- BCSF
- Stock Information
- Founded
- RCUS 2015
- BCSF 2015
- Country
- RCUS United States
- BCSF United States
- Employees
- RCUS N/A
- BCSF N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- BCSF Finance/Investors Services
- Sector
- RCUS Health Care
- BCSF Finance
- Exchange
- RCUS Nasdaq
- BCSF Nasdaq
- Market Cap
- RCUS 906.4M
- BCSF 1.0B
- IPO Year
- RCUS 2018
- BCSF 2018
- Fundamental
- Price
- RCUS $8.36
- BCSF $15.02
- Analyst Decision
- RCUS Buy
- BCSF Buy
- Analyst Count
- RCUS 10
- BCSF 2
- Target Price
- RCUS $23.75
- BCSF $16.50
- AVG Volume (30 Days)
- RCUS 1.2M
- BCSF 263.4K
- Earning Date
- RCUS 08-07-2025
- BCSF 08-05-2025
- Dividend Yield
- RCUS N/A
- BCSF 11.24%
- EPS Growth
- RCUS N/A
- BCSF N/A
- EPS
- RCUS N/A
- BCSF 1.75
- Revenue
- RCUS $141,000,000.00
- BCSF $284,993,000.00
- Revenue This Year
- RCUS N/A
- BCSF N/A
- Revenue Next Year
- RCUS $28.73
- BCSF N/A
- P/E Ratio
- RCUS N/A
- BCSF $8.56
- Revenue Growth
- RCUS N/A
- BCSF N/A
- 52 Week Low
- RCUS $6.50
- BCSF $13.20
- 52 Week High
- RCUS $18.98
- BCSF $19.21
- Technical
- Relative Strength Index (RSI)
- RCUS 39.01
- BCSF 43.78
- Support Level
- RCUS $7.91
- BCSF $14.71
- Resistance Level
- RCUS $8.87
- BCSF $15.17
- Average True Range (ATR)
- RCUS 0.48
- BCSF 0.26
- MACD
- RCUS -0.14
- BCSF -0.02
- Stochastic Oscillator
- RCUS 8.24
- BCSF 30.16
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.